8-K: Owens & Minor Announces Preliminary Q4 and Full Year 2024 Results, Initiates Financing for Rotech Acquisition

Owens & Minor released preliminary financial results for the fourth quarter and full year 2024, alongside announcing the commencement of financing activities for the acquisition of Rotech Healthcare Holdings.

Summary

• Owens & Minor has announced preliminary financial results for the fourth quarter and full year 2024, which include a non-cash goodwill impairment charge of approximately $310 million related to its Apria division.
• The company's preliminary fourth-quarter revenue is estimated to be between $2.67 and $2.70 billion, with a net loss between $288 and $311 million, and adjusted EBITDA between $135 and $140 million.
• For the full year 2024, preliminary revenue is estimated to be between $10.67 and $10.70 billion, with a net loss between $355 and $378 million, and adjusted EBITDA between $520 and $525 million.
• The company is initiating a process to raise additional debt to finance the acquisition of Rotech Healthcare Holdings, which is expected to close in the first half of 2025.
• Owens & Minor reduced total debt by over $240 million in 2024, and the company expects to continue deleveraging over the next few years.
• The Patient Direct segment showed solid mid-single-digit growth for the full year, with even higher growth in key categories.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net losses and goodwill impairment, although the company is taking steps to improve its financial position through strategic acquisitions and debt reduction. The positive growth in the Patient Direct segment and the financing for the Rotech acquisition provide some optimism, but the overall financial results are concerning.

Positives

• The company achieved solid mid-single-digit growth in its Patient Direct segment for the full year.
• Owens & Minor successfully reduced its total debt by over $240 million in 2024.
• The company's healthy free cash flow is expected to support the financing of the Rotech acquisition and deleveraging goals.
• The company is taking advantage of attractive capital markets to secure financing for the Rotech acquisition.
• The Rotech acquisition is expected to accelerate revenue and earnings growth, with adjusted EPS neutral in year 1 and ~$0.15 accretive in year 2.
• The company has a commitment to deleveraging to below 3.0x in ~24 months after closing the Rotech transaction.

Negatives

• The company expects a significant net loss for both the fourth quarter and the full year 2024.
• A non-cash goodwill impairment charge of approximately $310 million is expected within the Apria division.
• The goodwill impairment charge is primarily due to financial market changes, including a decline in Owens & Minor's stock price and rising interest rates, as well as anticipated changes in pricing of a capitated contract.

Risks

• The preliminary financial results are subject to final management review and audit.
• The company's ability to raise additional financing for the Rotech acquisition on favorable terms is not guaranteed.
• There is a risk that the proposed acquisition of Rotech will not be consummated in a timely manner or at all.
• The company faces risks related to the integration of Rotech's business, which may impact the expected synergies and financial performance.
• The company's actual results may differ materially from forward-looking statements due to various known and unknown risks and uncertainties.

Future Outlook

The company expects the Rotech acquisition to close in the first half of 2025 and anticipates it will accelerate revenue and earnings growth, with adjusted EPS neutral in year 1 and ~$0.15 accretive in year 2. The company also aims to deleverage to below 3.0x in ~24 months after closing the transaction.

Management Comments

• Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor, stated that the company is commencing a process to raise additional debt while the capital markets are attractive, to finance the acquisition of Rotech.
• Pesicka also noted that the company's healthy free cash flow provides the vehicle for this proposed financing as well as helping them achieve their deleveraging goals over the next few years.
• Pesicka added that the company's healthy top-line performance in 2024 is representative of the demand for their products and services across both segments of their business.
• Pesicka highlighted the full-year performance of the Patient Direct segment, which posted solid mid-single digit growth, and even higher in key categories.
• Pesicka also mentioned that in a year of meaningful reinvestment in the business, the company was able to reduce total debt by over $240 million.

Industry Context

This announcement comes as the healthcare industry continues to see a shift towards home-based care, with companies like Owens & Minor expanding their presence in this market through acquisitions like Rotech. The company's focus on the Patient Direct segment aligns with the broader trend of increasing demand for home healthcare services.

Comparison to Industry Standards

• Owens & Minor's acquisition of Rotech is similar to other moves in the healthcare industry where companies are consolidating to expand their reach in the home healthcare market, such as CVS Health's acquisition of Signify Health and UnitedHealth Group's acquisition of LHC Group.
• The company's focus on deleveraging is a common goal for companies in the healthcare sector, especially after making significant acquisitions, as seen with companies like Cardinal Health and McKesson.
• The reported net loss and goodwill impairment are not uncommon in the healthcare industry, especially when companies are undergoing significant strategic changes or facing market fluctuations, similar to what has been seen with companies like Baxter International and Medtronic.
• The company's Patient Direct segment growth is in line with the industry trend of increasing demand for home-based care, which is also being seen by companies like AdaptHealth and Option Care Health.

Stakeholder Impact

• Shareholders will be impacted by the net losses and goodwill impairment, but may see long-term benefits from the Rotech acquisition and debt reduction.
• Employees may experience changes due to the integration of Rotech, but the company's growth strategy could provide new opportunities.
• Customers may benefit from the expanded product offerings and services resulting from the Rotech acquisition.
• Suppliers may see increased business opportunities as the company expands its operations.
• Creditors will be impacted by the company's debt reduction efforts and new financing activities.

Next Steps

• Owens & Minor will host a conference call for investors and analysts on February 28, 2025, to discuss the fourth quarter and full year 2024 financial results.
• The company will continue the process of raising additional debt to finance the Rotech acquisition.
• The company will work towards closing the Rotech acquisition in the first half of 2025.
• The company will focus on integrating Rotech and achieving the expected synergies.
• The company will continue to deleverage and reduce its debt.

Key Dates

Keywords

Owens & Minor, Rotech Healthcare, Acquisition, Financial Results, Debt Financing, Goodwill Impairment, Patient Direct, Healthcare Solutions, EBITDA, Net Loss